×
About 988 results

ALLMedicine™ Ameloblastoma Center

Research & Reviews  380 results

Extended total temporomandibular joint reconstruction prosthesis: A comprehensive analy...
https://doi.org/10.1016/j.jormas.2023.101404
Journal of Stomatology, Oral and Maxillofacial Surgery; Khattak YR, Arif H et. al.

Feb 1st, 2023 - Alloplastic total temporomandibular joint replacement (TMJR) is the treatment of choice for end-stage temporomandibular joint diseases. Extended TMJR (eTMJR) is a modification of the standard alloplastic fossa-condyle joint that includes component...

A Rare Case of Deceptive Maxillary Ameloblastoma.
https://doi.org/10.1177/01455613231154060
Ear, Nose, & Throat Journal; Wu Y, Tian Y et. al.

Jan 31st, 2023 - Ameloblastoma (AM) is a rare epithelium-derived odontogenic tumor, mostly involving the mandible and less often the maxilla. Most AMs are benign and characterized by indolence and local invasiveness, with a high recurrence rate. Herein, we present...

Genetic Heterogeneity and Enrichment of Variants in DNA-Repair Genes in Ameloblastoma.
https://doi.org/10.1111/jop.13410
Journal of Oral Pathology & Medicine : Official Publicati... Awotoye W, Whitt J et. al.

Jan 31st, 2023 - Ameloblastomas are a group of common odontogenic tumors that originate from the dental epithelium. These tumors are aggressive in nature and present as slow growing painless cortical expansion of the jaw. Histologically, the follicular and plexifo...

Genomic profiling and precision medicine in complex ameloblastoma.
https://doi.org/10.1002/hed.27294
Head & Neck; Gates JC, Clark AP et. al.

Jan 17th, 2023 - Ameloblastoma may present a significant treatment challenge in the locally advanced, recurrent and metastatic setting. Comprehensive genomic profiling (CGP) can identify targetable genomic alterations to aid in treatment. Ameloblastoma samples wer...

The molecular basis of odontogenic cysts and tumours.
https://doi.org/10.1111/jop.13401
Journal of Oral Pathology & Medicine : Official Publicati... Gomes IP, Bastos VC et. al.

Jan 12th, 2023 - The advances in molecular technologies have allowed a better understanding of the molecular basis of odontogenic cysts and tumours. PTCH1 mutations have been reported in a high proportion of odontogenic keratocyst. BRAF p.V600E are recurrent in am...

see more →

Clinicaltrials.gov  2 results

Clinical Evaluation of Fenestration Decompression Combined With Secondary Curettage for Ameloblastoma of the Jaw: Retrospective Radiographic Analysis
https://clinicaltrials.gov/ct2/show/NCT04987515

Nov 22nd, 2021 - Objectives: To investigate the outcomes of fenestration decompression combined with secondary curettage (FDSC) in the surgical treatment of jaw ameloblastoma. Methods: Medical records of patients diagnosed as multicystic ameloblastoma (MA) or unic...

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
https://clinicaltrials.gov/ct2/show/NCT02367859

Jan 21st, 2020 - PRIMARY OBJECTIVES: I. To observe the response rate of ameloblastoma to dabrafenib and trametinib at 6 weeks. SECONDARY OBJECTIVES: I. Feasibility and safety in this patient population. II. Response will be assessed pathologically. III. Two main h...

see more →

News  1 results

FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
https://www.onclive.com/view/fda-approves-dabrafenib-plus-trametinib-for-braf-v600e-mutated-unresectable-or-metastatic-solid-tumors

Jun 23rd, 2022 - The FDA has granted an accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation w...

see more →

Patient Education  12 results see all →